Todd Druley is the Chief Medical Officer for ArcherDX, Inc and an Associate Professor of Pediatrics, Developmental Biology and Genetics at Washington University School of Medicine. He obtained a Bachelor’s in Cell and Structural Biology and a minor in Chemistry from the University of Illinois. He then completed the MD/PhD program at the University of Illinois where he studied mechanisms of chemotherapy resistance. In 2002, Dr. Druley joined Washington University as a pediatric resident and has remained; completing his fellowship in Pediatric Hematology and Oncology and joining the faculty in pediatric hematology and oncology in 2008. Clinically, Druley established and directs the Pediatric Cancer Predisposition Program. Scientifically, the Druley lab has focused on abnormal childhood development and pediatric cancer as well as genomic methodology development and application to complex disease. In 2019, Druley moved to part-time status at Washington University, keeping his academic lab, but taking a new challenge as the Chief Medical Officer for ArcherDX, which specializes in democratizing high-throughput, molecular barcoded nucleic acid sequencing for research and molecular diagnostics.